Description

Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial insemination, which can be performed using either the husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies, ranging from conventional IVF with embryo transfer to IVF utilizing intracytoplasmic sperm injection (ICSI). To complement its ARS treatments, the company also furnishes a range of supportive services such as nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Beyond fertility-specific care, Jinxin Fertility Group extends its operations to include management services, general medical care encompassing gynecology, urology, and internal medicine, as well as ambulatory surgery center facilities and other ancillary medical services. Furthermore, the company conducts pre-implantation genetic screening tests. Its business scope also diversifies into investment management, management consulting, and real estate development and operation. Jinxin Fertility Group Limited was established in 2003 and has its corporate headquarters located in Chengdu, China.